10 results
To determine the influence of esomeprazole on the AUC of regorafenib in patients with mCRC or GIST.
To evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.The primary efficacy endpoint of this study is * Overall survivalThe secondary efficacy endpoints of this…
The purpose of this study is to determine if the combination of relatlimab and nivolumab improves overall survival (OS) in all randomized participants and participants with PD-L1 CPS >= 1 with later-line metastatic colorectal cancer compared…
The primary objective is progression-free survival (PFS); defined as the time from randomization to the date of the first documented tumor progression; determined using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or death due…
The objective of this study is to evaluate efficacy and safety of regorafenib in patients with HCC who have progressed after sorafenib.
Primary objectives* To assess the tolerability of regorafenib combined with paclitaxel.Secondary objectives* To assess the effect of regorafenib on uptake of paclitaxel in OGC metastases.* To assess the effect of regorafenib on regorafenib targets…
The main objective of this treatment protocol is to study the efficacy on the treatment response after adding a single gift of Mylotarg. Furthermore, monitoring of toxicity and long term efficacy is also important.
This protocol is designed to determine the safety, tolerability, and efficacy of SGI-110 in combination with irinotecan in previously treated patients with metastatic colorectal cancer who progressed on irinotecan.
Primary Objective:* The primary objective is to demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST),…
General aim; To dertemine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety to warrant further evaluation as a first line treatment for metastatic GIST.